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Abstract 
BACKGROUND: Detection of KRAS mutations in cell-free circulating tumor DNA (ctDNA) 
in blood has the potential to enable early diagnosis of primary tumors. However, the sensitivity 
of this assay is often too low in the early stages of disease, because the number of ctDNA 
molecules with somatic mutations is very low compared with wild type. Therefore, we 
developed a novel approach to specifically enrich mutant KRAS alleles using biotinylated 
pyrrole–imidazole (PI) polyamides designed to bind to the minor groove of the mutant B-DNA. 
METHODS: We investigated the clinical use of this approach to detect KRAS mutations in 
ctDNA from patients with colorectal cancer (CRC). Biotinylated PI polyamides were 
synthesized to target common KRAS codon 12 mutations, and 40 matched tumor and serum 
samples were collected. The results from the digital PCR analysis were compared before and 
after the enrichment assay. 
RESULTS: Tumor characterization revealed 17 patient tumors with KRAS mutations, with six 
G12V and 11 G12D mutations. Among the nine patients with non-metastatic CRC bearing 
tumor-associated KRAS mutations, the diagnostic sensitivity of ctDNA analysis after 
enrichment assay was significantly higher than that before the enrichment assay (88.9% vs. 
11.1%, P < 0.01). Among the eight patients with metastatic CRC bearing tumor-associated 
KRAS mutations, the diagnostic sensitivities before and after the enrichment assay did not differ 
significantly (100% vs. 75.0%, P = 0.47). 
CONCLUSIONS: This newly developed approach for the enrichment of mutant KRAS alleles 
significantly improved the identification of KRAS mutations in ctDNA from patients with 
non-metastatic CRC. 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Mutations in ras genes, particularly H-ras, N-ras, and K-ras, are commonly identified in many 
types of tumors and have been implicated in the development of human cancer (1, 2). Of these 
genes, mutations in KRAS are much more frequent than NRAS or HRAS (3), with a frequency of 
90% in pancreatic cancer (4), 35% in lung cancer (5), and 30%–60% in colon cancer (6, 7). 
Thus, KRAS mutations are predicted to be promising biomarkers for the early diagnosis of 
primary tumors. 
Currently, histological examination of tumor tissues is the gold standard for diagnosing 
the presence of mutations in KRAS. However, examining tissue samples has some disadvantages, 
as tumors and metastases are not always accessible for biopsy, collection of biopsies often 
requires invasive procedures, and intratumoral heterogeneity is not well understood. 
An alternative approach to overcome these issues is the analysis of cell-free circulating 
tumor DNA (ctDNA). Several groups are currently developing methods to detect somatic 
mutations with the aim of discovering markedly higher cell-free DNA (cfDNA) concentrations 
in the blood of patients with cancer, in particular, KRAS from plasma and serum (8–11). New 
techniques, such as digital polymerase chain reaction (dPCR) (12, 13), as well as beads, 
emulsions, amplification, and magnetics (known as BEAMing) (14, 15), allow highly sensitive 
detection of cancer-specific DNA in the blood. In patients with late-stage cancer, measurement 
of ctDNA can be used as a liquid biopsy to predict response to targeted therapies (11, 12, 15). 
Use of ctDNA measurement also raises the possibility of screening and diagnosing 
before cancers becomes clinically detectable (12, 16). However, the diagnostic sensitivity of 
ctDNA analysis for cancer detection is often too low due to very low levels of ctDNA and 
detection of background of nontumor-derived cfDNA (13). Therefore, patients can only be 
diagnosed at advanced stages with high tumor burden and high ctDNA concentrations. 
Due to the difficulties in detecting cancer-specific mutations at the early disease stage, 
we developed a novel approach to specifically enrich mutant KRAS alleles in ctDNA using 
biotinylated pyrrole–imidazole (PI) polyamides. Hairpin pyrrole (Py)–imidazole (Im) 
polyamides bind with high affinity to the minor groove of specific sequences of the Watson–
Crick B-form DNA; Py moieties preferentially bind T, A, and C bases, but not G, whereas Im is 
a G-reader (17). Therefore, we synthesized biotinylated PI polyamides to target common KRAS 
codon 12 mutations to enhance the detection of KRAS mutations in ctDNA. The results from the 
dPCR analysis were compared before and after the enrichment assay and demonstrated an 
increased sensitivity using this approach to detect KRAS mutations in patients with colorectal 
cancer (CRC). 
 
Materials and Methods 
 
Synthesis of biotinylated PI polyamides 
Fig. 1 shows the structures of the biotinylated PI polyamides (KRAS4 and KRAS5). KRAS4 
and KRAS5 were designed to recognize KRAS G12S/G12C and G12V/G12D mutations, 
respectively (Fig. 1). Biotinylated PI polyamides were synthesized using a stepwise reaction 
according to a previously described Fmoc solid phase protocol (18–21). Synthesis was 
performed using a Peptide Synthesizer (PSSM-8, Shimadzu Industry) with a computer-assisted 
operation system on a 10 µmol scale (19.6 mg of Fmoc–β-alanine Wang resin). Following 
synthesis, N,N-dimethylpropanediamine (Dp) was mixed with the resin then heated to 65 ºC for 
2 h to detach the PI polyamides from the resin. Puriﬁcation of PI polyamides was performed 
using a high-performance liquid chromatography (HPLC) LC-20 (SHIMAZU Industry), using a 
10 mm × 150 mm Phenomenex Gemini-NX3u 5-ODS-H reverse-phase column in 0.1% acetic 
acid in water with acetonitrile as the eluent, a ﬂow rate of 10 mL/min, and a linear gradient from 
0% to 66.7% acetonitrile over 20 min, with detection at 310 nm. Collected fractions were 
analyzed by liquid chromatography mass spectroscopy. After purification, N-terminal 
biotinylation was performed to produce KRAS4 and KRAS5 by incubating the cleavage product 
in the presence of biotin, PyBOP, and DIEA for 2 h. After solvent evaporation, the reaction 
product was characterized and purified by liquid chromatography (Shimadzu, Prominence 
HPLC) using a linear gradient of acetic acid (0.1%) in acetonitrile and water (30%–75%, linear 
over 30 min). Peaks were visualized at 310 nm for compound characterization. 
 
Surface plasmon resonance assay 
All SPR experiments were performed on a Biacore X100 (GE Healthcare) at 25ºC as described 
previously (18). Biotinylated hairpin KRAS G12D mutated nucleotide (5’biotin- 
TACATCTGATGGCGTATTAAGTTTTCTTAATACGCCATCAGATGTA-3', Hokkaido 
System Science), KRAS G12V mutated nucleotide (5’biotin- 
TACATCTGTTGGCGTATTAAGTTTTCTTAATACGCCAACAGATGTA-3', Hokkaido 
System Science) and KRAS wild nucleotide (5’biotin- 
TACATCTGGTGGCGTATTAAGTTTTCTTAATACGCCACCAGATGTA-3', Hokkaido 
System Science) were immobilized on a streptavidin coated SA sensor chip at a flow rate of 10 
µL/min to obtain the required immobilization level (up to approximately 1000 resonance units 
(RU)). Samples were dissolved in HBS-EP buffer (10 mM 4-(2-hydroxyethyl)- 
1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 3 mM ethylenediamine tetraacetic 
acid (EDTA), and 0.005% surfactant P20) with 0.1% DMSO at 25ºC, pH 7.4 for the 
experiment. 
 
 
Enrichment protocol using biotinylated PI polyamides 
Fig. 2 shows a schematic representation of the enrichment assay and outlines its three distinct 
steps. (1) Preparation of the magnetic beads was performed as follows. After removing the 
suspension solution from streptavidin magnetic beads (Magnosphere MS300/Streptavidin, 
JSR Corporation, Tokyo, Japan), the beads were washed with buffer (10 mM Tris–HCl, pH 
7.4); 0.5 mM EDTA; 1 M NaCl; and 0.1% Tween20) and then resuspended in the same buffer. 
The resuspended streptavidin magnetic beads were mixed with biotinylated PI polyamides and 
centrifuged at 1300 rpm for 15 min. After removing the buffer from beads and biotinylated PI 
polyamides, the beads were washed with buffer and resuspended in water. (2) Beads and 
biotinylated PI polyamides were then incubated with DNA fragments while being centrifuged at 
1300 rpm for 1 h. After removing the supernatant solution and wild type DNA alleles, mutant 
DNA alleles with beads and biotinylated PI polyamides were washed with water. (3) Then, 
enriched mutant DNA alleles were resuspended in Tris–EDTA buffer and DNA was eluted 
from the beads and biotinylated PI polyamides after heating at 97 °C for 30 min. 
 
Patients 
A total of 40 tumor samples and matched serum samples were obtained from 40 patients 
between October 2010 and November 2016 at the Chiba Cancer Center (Chiba, Japan), and 
were analyzed in the present study. The residual serum samples used in the study were frozen 
and stored immediately after routine blood chemistry analysis prior to surgical treatment. All 
the samples were histologically diagnosed as CRC and were obtained prior to therapy. None of 
the patients received preoperative chemotherapy or radiotherapy. As controls, 10 healthy 
individuals were recruited with no prior history of any cancer. 
All the patients provided written informed consent for use of their serum and clinical 
data. The present study was reviewed and approved by the ethics committee of the Chiba 
Cancer Center, and the protocol was displayed on a notice board for inpatients and outpatients 
(number 1875). The study was carried out in accordance with the World Medical Association’s 
Declaration of Helsinki. 
 
Analysis of KRAS mutations in colorectal tumor tissue 
Tissue samples were collected by biopsy or surgical resection. DNA was purified from 
formalin-fixed, paraffin-embedded specimens using a QIAamp DNA Mini kit (Qiagen, 
Valencia, CA, USA) according to the manufacture’s protocol (22). Analysis of KRAS mutation 
in primary tumors was performed using an amplification refractory mutation system 
(ARMS)-Scorpion or Luminex assays as described previously (23, 24). 
 
Blood collection and cfDNA extraction 
Blood samples were collected from patients into tubes containing EDTA at the ﬁrst visit. The 
samples were centrifuged at 3000 × g at 4 °C to separate serum from peripheral blood cells and, 
following blood chemistry analysis, samples were stored at–80 °C until analyzed further. 
ctDNA was extracted from 500 µL of serum using the Maxwell RSC ccfDNA Plasma Kit and 
an automated Maxwell RSC Instrument (Promega, Madison, Wisconsin, USA) according to the 
manufacturer’s protocol, as described previously (25). Extracted DNA was quantified using a 
Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). 
 
Droplet digital PCR 
We used a QX200 droplet digital PCR (ddPCR) system (Bio-Rad, Hercules, CA, USA) to 
analyze the presence of mutations and wild type status in KRAS, as described previously (25, 
26). ctDNA from CRC patients and plasmid DNA were amplified using the 
ddPCR KRAS Screening Multiplex Kit (Bio-Rad) capable of detecting the seven most common 
KRAS mutations. To confirm the results obtained using the multiplex ddPCR, an additional 
analysis was performed using a duplex ddPCR approach using the Prime-PCR ddPCR Mutation 
Detection Assay Kit (Bio-Rad) (G12V and G12D). A volume of 8 µL of DNA template was 
added to 10 µL of ddPCR Supermix for Probes (Bio-Rad) and 2 µL of the primer/probe mixture. 
Droplets were generated using the Automated Droplet Generator (Auto-DG, Bio-Rad), where 
the reaction mix was added together with Droplet Generation Oil for Probes (Bio-Rad). The 
emulsion was added to a thermal cycler, starting with enzyme activation of 10 min at 95 °C, 
followed by 40 cycles of 30 s at 94 °C and 1 min at 60 °C, and finishing with 10 min at 98 °C 
for enzyme deactivation. When the cycling was complete, the fluorescence signal was measured 
for each droplet. Droplets were analyzed using the QX200 Droplet Reader (Bio-Rad) for 
fluorescent measurement of FAM and HEX probes. Data from the fluorescence signals were 
analyzed using the Quanta software program, version 1.4.0 (Bio-Rad), in accordance with the 
manufacturer's protocol, to determine the number of droplets positive for wild type KRAS and/or 
KRAS mutations. In the present study, the cutoff values for mutations were determined using 
serum cfDNA from 10 healthy individuals, and were set at 1.0 copy per reaction. 
 
Titration study using plasmid DNA and genomic DNA 
A titration study was initially performed to evaluate the enrichment of targeted DNA alleles 
using plasmid DNA containing four KRAS mutations (G12V, G12D, G12S, and G12C) and wild 
type genomic DNA isolated from human whole blood. Plasmid DNAs were amplified by PCR 
and cloned into the plasmid, pCRH2.1 (Thermo Fisher Scientific, Waltham, MA, USA) (22). 
The synthesized templates were verified by sequencing and used for the titration study (fraction 
of mutant alleles: 10%, 1%, and 0.1%). 
 
Statistical analysis 
Means and standard deviations (SDs) of fold enrichments were calculated for the enrichment 
assay in the titration samples. Fold enrichment between titration samples was compared using a 
paired t test. For diagnostic performance, accuracy, sensitivity, and specificity, data are 
presented as percentages. The diagnostic performance of each modality was statistically 
analyzed by Fisher’s exact test. P < 0.05 for two-tailed tests was regarded as significant. SPSS 
software, version 17.0 (SPSS Inc, Chicago, IL, USA) was used to perform statistical analyses. 
 
RESULTS 
 
Biotinylated PI polyamides target KRAS codon 12 mutants 
Biotinylated PI polyamide (KRAS5) was designed to recognize KRAS G12V/G12D mutations. 
Surface plasmon resonance (SPR) analysis was conducted to evaluate the binding affinities of 
KRAS5 to the target DNAs, KRAS G12D (GAT), KRAS G12V (GTT), and KRAS wild type 
(GGT) sequence, as described previously (Fig. 3 and Table 1) (18). KRAS mutations (G12D 
and G12V) showed substantial SPR responses, while wild type sequence did not show a 
detectable signal, suggesting that KRAS5 was unable to bind to the wild type sequence. 
Dissociation equilibrium constants (KD = kd/ka, where kd and ka are the dissociation and 
association rate constants, respectively) between the free and bound states of KRAS5 were 
determined by fitting the SPR results as an exponential decay model (Fig. 3) (27). G12D (3.04 
× 10–7 M) and G12V (2.45 × 10–7 M) were two orders of magnitude lower than the wild type 
(167 × 10–7 M, Table 1) in KD, indicating that KRAS5 had a lower affinity for the wild type 
sequence (Table 1). 
 
Fold enrichment in the titration study 
Each plasmid DNA (G12V, G12D, G12S, and G12C) was spiked into 50 ng of whole blood 
DNA, and titration samples (fraction of mutant alleles: 10%, 1%, and 0.1%) were prepared. An 
enrichment assay was then performed using these samples. The fold enrichment was calculated 
from the ddPCR results, and defined as the fractional abundance of the assay divided by that of 
the titration samples. 
First, a multiplex analysis was performed for each plasmid sample. For the G12V 
alleles, the mean (± SD) fold of the enrichment assay in the 10%, 1%, and 0.1% mutant 
fractions were 2.85 ± 0.74, 8.17 ± 1.66, and 25.99 ± 8.70, respectively. For the G12D alleles, 
the mean folds in the 10%, 1%, and 0.1% mutant fraction were 2.63 ± 0.60, 8.15 ± 2.15, and 
26.98 ± 14.08, respectively. For the G12S alleles, the mean folds in the 10%, 1%, and 0.1% 
mutant fraction were 2.98 ± 0.81, 9.02 ± 2.28, and 22.45 ± 8.84, respectively. Finally, for the 
G12C alleles, the mean folds in the 10%, 1%, and 0.1% mutant fraction were 2.85 ± 0.90, 7.42 
± 1.61, and 23.24 ± 7.40, respectively. For each KRAS mutation, the folds were significantly 
higher in the 1% mutant fraction compared with the 10% mutant fraction (P < 0.05) and were 
also higher in the 0.1% mutant fraction compared with 1% mutant fraction (P < 0.05) (Fig. 4).  
To confirm the results obtained using multiplex ddPCR, we conducted additional 
analyses with a duplex ddPCR approach, in which only two molecular targets were detected in 
each experiment (i.e., wild type and a given mutant sequence) (12). For the G12V alleles, the 
mean (± SD) folds of the enrichment assay in the 10%, 1%, and 0.1% mutant fraction were 2.07 
± 0.22, 9.66 ± 2.26, and 42.24 ± 6.87, respectively. For the G12D alleles, the mean folds in the 
10%, 1%, and 0.1% mutant fraction were 1.99 ± 0.26, 8.65 ± 1.13, and 36.54 ± 6.88, 
respectively. For each KRAS mutation, the mean folds were significantly higher in the 1% 
mutant fraction compared with the 10% mutant fraction (P < 0.05) and were also higher in the 
0.1% mutant fraction compared with the 1% mutant fraction (P < 0.05) (Fig. 5). 
 
Patients’ characteristics 
Table 2 shows a summary of the patients’ characteristics. The median patient age was 64 (range 
39–82) years and there was a preponderance of males (n = 27, 67.5%). Primary tumors were 
located in the right-sided colon in 12 (30.0%) patients, and the left-sided colon in 28 (70.0%) 
patients. Two (5.0%), four (10.0%), 11 (27.5%), and 23 (57.5%) patients had stage I, II, III, and 
IV cancer, respectively. The median carcinoembryonic antigen (CEA) level was 23.5 ng/mL 
(range, 1.7–7317.9 ng/mL). Tumor characterization revealed that 17 patient tumors were 
positive for KRAS mutations, of which six (35.3%) were G12V mutations and 11 (64.7%) were 
G12D. 
 
KRAS mutation detection in ctDNA 
The median serum DNA concentration in CRC patients was 107.5 ng/mL (range, 0.0–3660.0 
ng/mL), and the median DNA concentration in metastatic CRC patients was significantly higher 
than that of non-metastatic CRC patients (0.0 ng/mL vs. 359.0 ng/mL, P < 0.01). 
First, dPCR analysis was performed in 40 ctDNA samples prior to the enrichment assay. 
The same samples were then analyzed by dPCR using biotinylated PI polyamides (KRAS5). 
Then, the dPCR analysis results were compared before and after the enrichment assay. 
Table 3 summarizes the findings of the dPCR analysis. KRAS mutations in ctDNA were 
detected in nine of the 40 (17.5%) patients before the enrichment assay and 16 of the 40 
(40.0%) patients after the enrichment assay. Fig. 6 shows representative cases (cases 1–9). 
Table 4 shows concordance of the data from the tumor-tissue analysis and ctDNA 
analysis. The diagnostic accuracy of the ctDNA analysis after enrichment assay was 
significantly greater than that before the enrichment assay (97.5% vs. 75.0%, P < 0.01). After 
the enrichment assay, ctDNA analysis had greater diagnostic sensitivity compared with that 
before the enrichment assay (94.1% vs. 41.2%, P < 0.01). While case 4 did not reach the cutoff 
value of 1.0 copy, there was a tendency toward an increase in mutant DNA after enrichment 
(Fig. 6). The diagnostic specificities before and after the enrichment assay were not 
significantly different (100% vs. 100%, P = 0.49). 
Fig. 7 shows the diagnostic sensitivities in terms of pathological stages. Among the 
nine patients with non-metastatic CRC bearing tumor-associated KRAS mutations, the 
diagnostic sensitivity after enrichment assay was significantly higher than that before the 
enrichment assay (88.9% vs. 11.1%, P < 0.01). Whereas, among the eight patients with 
metastatic CRC bearing tumor-associated KRAS mutations, the diagnostic sensitivities before 
and after the enrichment assay were not significantly different (100% vs. 75.0%, P = 0.47). 
 Discussion 
We developed a novel PI polyamide-based enrichment approach to target common 
KRAS codon 12 mutations (G12V, G12D, G12S, and G12C). In the titration study, greater 
enrichment effects were achieved in samples containing a lower fraction of mutant KRAS alleles. 
Our approach significantly improved the identification of KRAS mutations in ctDNA, 
particularly from patients with non-metastatic CRC. 
Hairpin Py–Im polyamides can be designed for specific 9-base pair recognition of the 
genome following Dervan’s recognition rule, as seen in natural minor groove binders, which 
undergo hydrogen bonding to DNA (17, 28). We demonstrated previously direct targeting of 
KRAS mutant DNA using alkylating polyamide conjugates that selectively recognize oncogenic 
codon 12 KRAS mutations (17). In the present study, we designed biotinylated PI polyamides to 
enrich mutant KRAS alleles in the presence of an excess of wild type alleles. 
ctDNA analysis, based on the “liquid biopsy” concept, was recently reported to 
represent a promising biomarker in patients with various types of cancer (29, 30). In metastatic 
CRC, identification and quantification of ctDNA can be used to evaluate response to treatment 
and assess the real-time development of resistance (11, 12, 15, 31). The reported diagnostic 
sensitivity ranged from 77.8% to 97.2% (11, 12, 15). Before the enrichment assay, our results 
showed a sensitivity of 75.0%, which was similar to but not as high as previous reports. These 
results may have been due to use of a small sample volume of 500 µL. Despite this limitation, 
we found a very high sensitivity (100%) after the enrichment assay. Therefore, our enrichment 
assay could be used in a cohort study with limited sample volumes, such as residual serum 
samples after blood chemistry analysis. 
Regarding early diagnosis of CRC, there are few reports on the sensitivity of ctDNA 
analysis to detect KRAS mutations. A previous report showed that mutant serum KRAS2 was 
detectable even in cases of small colonic polys (32). However, this study did not use 
quantitative analysis and did not have matched tumor and serum samples for all cases. Another 
recent study on non-metastatic CRC was able to detect 5.6% of tumor mutations by dPCR (33), 
which is not satisfactory as an early diagnostic biomarker. Thus, further improvement of 
techniques is required to define patients with early-stage CRC. The present study on 
non-metastatic CRC demonstrated that ctDNA analysis achieved an extremely high degree of 
diagnostic sensitivity (88.9%) following the enrichment assay. This may represent the best 
opportunity to cure CRC. One possible reason for the significant improvement in patients with 
non-metastatic CRC is that PI polyamides increased the selectivity when the fraction of mutant 
KRAS alleles decreased. This improvement is not likely artificial, since ctDNA analysis after 
enrichment assay achieved 100% specificity. 
In CRC patients, early detection of recurrence after surgery during follow-up is 
associated with improved survival (34–37). Computed tomography imaging improves the 
detection of recurrence, but is associated with radiation exposure. Furthermore, it can only 
detect residual disease when a sufficient tumor bulk is present (37, 38). While CEA is currently 
the standard biomarker used, it has limited sensitivity and specificity (38, 39). Thus, further 
improvement of strategies is required to detect minimal residual disease. Postoperative ctDNA 
detection provides direct evidence of remaining cancer cells and can identify patients at high 
risk of relapse (36, 40). In the present study, among patients with non-metastatic CRC bearing 
tumor-associated KRAS mutations, we were able to detect KRAS mutations in ctDNA after 
enrichment assay of CEA-negative patients. While our approach is not a perfect indicator, as 
biotinylated PI polyamides only targeted four KRAS mutations, its sensitivity is attractive. If 
ctDNA analysis after enrichment assay can reliably detect relapse, this would enable patients 
eligible for curative surgical resection or earlier implementation of systematic therapies to be 
identified. In addition, the potential benefit of this approach may have clinical implication in 
monitoring resistance to treatment and emergence of new KRAS mutations. Further study 
involving the longitudinal monitoring of patients is required to validate whether our enrichment 
technique allows early detection and monitor emergence of KRAS mutation after treatment. 
Pancreatic cancer exhibits a high frequency (75%–95%) of KRAS mutations (4, 41). 
Furthermore, in pancreatic cancer, the most frequent KRAS point mutations are located in two 
consecutive nucleotides in codon 12 (4). Therefore, KRAS codon 12 mutations in ctDNA 
represent an important potential biomarker of pancreatic cancer, which is fatal disease that is 
often diagnosed at advanced stages due to a lack of suitable techniques for early detection and 
diagnosis (30, 42). However, the role of KRAS mutations in the early diagnosis of pancreatic 
carcinoma remains controversial (43), because the diagnostic sensitivity of KRAS analysis is 
low (35%–38%) (13, 26). However, we believe that our enrichment assay could be 
advantageous in improving the diagnosis of KRAS-mutated ctDNA and could be also used for 
the early detection of pancreatic cancer. 
This study had several limitations as it was a single-center, retrospective, small study 
that used residual serum samples. In a previous study, the detection rates of KRAS mutations in 
serum and plasma DNA were almost equal, and both serum and plasma DNA could be used to 
detect prognostic biomarkers for pancreatic cancer (26). However, the use of plasma is 
recommended for the analysis of ctDNA due to lower concentrations of background wild type 
DNA (44). Further studies involving larger numbers of patients and using plasma samples is 
required to validate the utility of the enrichment of mutant KRAS alleles. Nonetheless, our 
approach clearly shows sufficiently improved detection of KRAS mutations in ctDNA from 
patients with non-metastatic CRC. 
In conclusion, enrichment of mutant KRAS alleles using biotinylated PI polyamides represents a 
feasible and effective method to identify KRAS mutations in ctDNA. Our results support the 
requirement for further evaluation of this newly developed approach to detect early diagnostic 
biomarkers for the management of CRC patients. 
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Figure 1 Structure of biotinylated pyrrole–imidazole polyamides. 
(A) Chemical structure of the PI polyamide, KRAS4. (B) KRAS4 targets G12S/G12C mutations. 
(C) Chemical structure of the PI polyamide, KRAS5. (D) KRAS5 targets G12V/G12D 
mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Schematic representation of the enrichment assay using biotinylated pyrrole–
imidazole polyamides. 
 
 
 
 
 
 
 
 
  
Figure 3 Surface plasmon resonance sensorgrams for the interaction between KRAS 5 and 
hairpin DNAs containing the sequence (a) KRAS GAT mutation, (b) KRAS GTT mutation, and 
(c) KRAS GGT wild type immobilized on the surface of a sensor chip SA. 
In (a) and (b), each of the five curves of the lowest, mid–low, middle, mid–high, and highest 
indicates concentrations of 200, 400, 600, 800, and 1000 nM PI polyamides, respectively. In (c), 
each of the five curves, the lowest, mid–low, mid–high, and highest indicate concentrations of 8, 
12, 16 and 20 µM PI polyamides, respectively. 
  
Figure 4 Relationship between fold of enrichment assay and fraction of mutant alleles. 
(A) Fold enrichment of KRAS5 for G12V alleles. (B) Fold enrichment of KRAS5 for G12D 
alleles. (C) Fold enrichment of KRAS4 for G12S alleles. (D) Fold enrichment of KRAS4 for 
G12C alleles. 
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Figure 5 Relationship between fold of enrichment assay and fraction of mutant alleles (duplex 
analysis). 
(A) Fold enrichment of KRAS5 for G12V alleles. (B) Fold enrichment of KRAS5 for G12D 
alleles. 
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Figure 6 One-dimensional plots of digital PCR analysis before and after enrichment assay. 
 (A, FAM-positive) Blue dots represent droplets containing KRAS mutation. (B, HEX-positive) 
Green dots represent droplets containing wild type KRAS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7 Diagnostic sensitivities, in terms of pathological stages. 
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Figure 5.  
Status Sequecne KD[10-7 M]a ka[103 M-1S-1]b kd[10-3 S-1]c 
G12D GAT 3.04 79.3 2.41 
G12V GTT 2.45 105 2.58 
WT GGT 167 1.13 1.88 
 
Table 1 Binding affinities of KRAS5 with DNAs of KRAS mutations (G12D and G12V) or 
KRAS wild type (WT). 
a Dissociation Constant, b Association rate constant, c Dissociation rate constant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N = 40 
Age, median (range), years 64 (39–82) 
Sex (male: female) 27：13 
Location (right-sided: left-sided) 12：28 
Stage of disease (UICC)  
  Ⅰ 2 
  Ⅱ 4 
  Ⅲ 11 
  Ⅳ 23 
CEA (ng/mL) 23.5 (1.7–7317.9) 
KRAS, primary tumour  
  wild-type 23 
  mutants 
  (G12V: G12D) 
17 
(6:11) 
 
Table 2 Patients’ characteristics. 
CEA, carcinoembryonic antigen. 
 
 
 
 
 
 
 
  Before enrichment assay  After enrichment assay 
Case Sex 
Age, 
years 
Primary 
site 
Stage 
CEA,  Concentration, KRAS status,  Mutant (Copies/µL) 
FA (%) 
Mutant (Copies/µL) 
FA (%) 
< 5.0 ng/mL  ng/mL of serum primary Wild (Copies/µL) Wild (Copies/µL) 
1 M 71 Rectum Ⅰ 3.4 60 G12D 
n.d. 
– 
13.9 
81.8 
1.6 3.1 
2 F 82 A-colon Ⅰ 2.5 < 20 G12V 
n.d. 
– 
5.9 
79.7 
1.5 1.5 
3 M 73 Rectum Ⅱ 10 < 20 G12V 
1.7 
48.6 
5.2 
78.8 
1.8 1.4 
4 M 71 Cecum Ⅱ 4.8 < 20 G12V 
n.d. 
– 
n.d. 
– 
1.2 n.d. 
5 M 79 A-colon Ⅲ 6.3 < 20 G12D 
n.d. 
– 
20.1 
61.8 
1.6 12.4 
6 M 45 Rectum Ⅲ 22.5 60 G12D 
n.d. 
– 
8.6 
70.5 
5.5 3.6 
7 F 72 Cecum Ⅲ 40.2 < 20 G12D 
n.d. 
– 
4.1 
75.9 
4.5 1.3 
8 M 49 S-colon Ⅲ 12.5 < 20 G12D 
n.d. 
– 
3 
63.8 
1.2 1.7 
9 M 65 S-colon Ⅲ 18.5 122 G12V 
n.d. 
– 
5.5 
68.8 
9.3 2.5 
10 F 74 Cecum Ⅳ 12.4 199 G12D 
n.d. 
– 
1.9 
37.3 
5 3.2 
11 F 77 S-colon Ⅳ 101.5 120 G12D 
1.9 
21.1 
3 
40.5 
7.1 4.4 
12 F 49 Rectum Ⅳ 24.5 343 G12D 
9 
22.6 
7 
42.4 
30.9 9.5 
13 F 68 A-colon Ⅳ 329.5 231 G12V 
7.1 
26.3 
5.1 
34.7 
19.9 9.6 
14 M 61 D-colon Ⅳ 203 1040 G12D 
48 
33.6 
7 
34.1 
95 13.5 
15 F 56 S-colon Ⅳ 717 1690 G12V 7.9 0.6 3.9 1.5 
1240 250 
16 M 74 A-colon Ⅳ 498.4 3660 G12D 
42 
38.4 
12.5 
43.1 
67.4 16.5 
17 F 47 S-colon Ⅳ 10.9 100 G12D 
n.d. 
– 
1.4 
31.8 
11 3.1 
18 M 68 S-colon Ⅱ 21.2 < 20 WT 
n.d. 
– 
n.d. 
– 
1 n.d. 
19 F 65 S-colon Ⅱ 10.6 60 WT 
n.d. 
– 
n.d. 
– 
7.2 2.8 
20 M 60 Rectum Ⅲ 4.6 < 20 WT 
n.d. 
– 
n.d. 
– 
2.1 n.d. 
21 M 57 S-colon Ⅲ 2.5 110 WT 
n.d. 
– 
n.d. 
– 
10.9 4.5 
22 M 75 Rectum Ⅲ 80.4 < 20 WT 
n.d. 
– 
n.d. 
– 
1 1 
23 M 60 S-colon Ⅲ 46.4 < 20 WT 
n.d. 
– 
n.d. 
– 
1.6 n.d. 
24 M 58 Rectum Ⅲ 55.8 67 WT 
n.d. 
– 
n.d. 
– 
5.3 3.8 
25 M 46 Rectum Ⅲ 4.5 54 WT 
n.d. 
– 
n.d. 
– 
4.3 4.3 
26 M 71 A-colon Ⅳ 5 60 WT 
n.d. 
– 
n.d. 
– 
3.4 2.5 
27 M 59 Rectum Ⅳ 775 169 WT 
n.d. 
– 
n.d. 
– 
19 6.5 
28 M 64 S-colon Ⅳ 7.8 < 20 WT 
n.d. 
– 
n.d. 
– 
1.6 4.2 
29 M 72 S-colon Ⅳ 183.8 1500 WT 
n.d. 
– 
n.d. 
– 
263 43.6 
30 F 55 S-colon Ⅳ 1.7 < 20 WT 
n.d. 
– 
n.d. 
– 
3.1 n.d. 
31 M 54 S-colon Ⅳ 54.3 105 WT n.d. – n.d. – 
12.2 4.3 
32 M 61 S-colon Ⅳ 2.4 2170 WT 
n.d. 
– 
n.d. 
– 
419 15.7 
33 M 39 S-colon Ⅳ 647.8 1330 WT 
n.d. 
– 
n.d. 
– 
194 5.6 
34 F 69 T-colon Ⅳ 75.3 359 WT 
n.d. 
– 
n.d. 
– 
40.5 7.2 
35 M 59 S-colon Ⅳ 7317.9 1230 WT 
n.d. 
– 
n.d. 
– 
80 7.4 
36 M 69 S-colon Ⅳ 4.1 194 WT 
n.d. 
– 
n.d. 
– 
21.1 4.8 
37 M 56 T-colon Ⅳ 3690.1 476 WT 
n.d. 
– 
n.d. 
– 
48.9 10.2 
38 F 64 A-colon Ⅳ 616.7 634 WT 
n.d. 
– 
n.d. 
– 
93 12.3 
39 M 61 Rectum Ⅳ 60.7 454 WT 
n.d. 
– 
n.d. 
– 
27.5 18 
40 F 75 A-colon Ⅳ 2950 1630 WT n.d. – n.d. – 
 
Table 3 Digital PCR analysis of ctDNA samples before and after enrichment assay. 
A-colon, ascending colon; S-colon, sigmoid colon; D-colon, descending colon; T-colon, 
transverse colon; CEA, carcinoembryonic antigen; WT, wild type; n.d., not detected; FA, 
fractional abundance. 
 
 
 
 
 
 
 
 
 
    Tumor-tissue analysis 
  Before enrichment assay Mutant WT Accuracy Sensitivity Specificity 
ctDNA analysis Mutant 7 0 75.00% 41.20% 100% 
 WT 10 23    
  Total 17 23       
  After enrichment assay Mutant WT Accuracy Sensitivity Specificity 
ctDNA analysis Mutant 16 0 97.5% 1 94.1% 1 100% 2 
 WT 1 23    
  Total 17 23       
 
Table 4 Concordance between tumor-tissue analysis and ctDNA analysis. 
1 P < 0.05 vs. before enrichment assay. 
2 No significant difference compared with before enrichment assay. 
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